Business
Hims & Hers Launches Peptides+ With Five Unapproved Compounded Treatments
On November 18, 2026, Hims & Hers launched Peptides+, a line of five compounded treatments (sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine) that the FDA has not approved for these wellness uses. The company says it will add BPC-157 and TB-500, two peptides covered by an interim HHS enforcement discretion policy. Here is what launched, the regulatory basis, and the open safety questions.
Quick answer
On November 18, 2026, the telehealth company Hims & Hers launched Peptides+, starting with five compounded products (sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine) that the FDA has not approved for these uses. The company plans to add the peptides BPC-157 and TB-500, which fall under an interim HHS enforcement discretion policy issued on October 30, 2026. That policy is not FDA approval, and the chief medical officer acknowledged the company does not yet have the clinical data usually available for such compounds.
Key takeaways
- →Hims & Hers began selling Peptides+ on November 18, 2026, starting with five compounded treatments: sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine. None is FDA approved for the marketed wellness uses.
- →The initial five products are not the peptides covered by the new federal policy. The October 30, 2026 HHS enforcement discretion policy applies to six peptides (BPC-157, TB-500, Epitalon, KPV, MOTS-c and Semax), which Hims says it will add later.
- →That HHS policy is interim enforcement discretion while a 503A bulks list is developed through rulemaking. It is not FDA approval, and HHS says it may revise or withdraw it.
- →Hims chief medical officer Dr. Anant Vinjamoori said the company does not have the clinical data usually available for such compounds. Independent researchers said dosing is not established and that telehealth-only oversight may be insufficient for unapproved injectables.
- →Hims opened an early-access waitlist in late October and said more than 10,000 people signed up within 15 days. Previewing the launch in its November 3 third-quarter report, it narrowed full-year revenue guidance to $3.13 billion to $3.15 billion and said peptide revenue would be immaterial this year.
Hims & Hers, one of the largest direct-to-consumer telehealth companies in the United States, has moved compounded peptides into the mainstream. On November 18, 2026 it launched Peptides+, a line that begins with five compounded treatments the FDA has not approved for the uses being marketed, and it says more will follow. The launch lands in the middle of an unsettled federal fight over whether and how such peptides may be compounded at all.
What Hims & Hers launched
Peptides+ opened on November 18, 2026 with five compounded products: sermorelin, a peptide that stimulates growth-hormone release and is marketed for recovery, body composition and anti-aging; glutathione, marketed for antioxidant support and recovery; NAD+, a coenzyme involved in cellular metabolism; vitamin B-12; and L-carnitine, an amino-acid derivative involved in turning fat into energy. The company's own page states that the products are not FDA approved and have not been evaluated by the regulator for safety, effectiveness, or quality.
Hims describes a clinician-led model: members start with an assessment by a licensed provider trained in peptide therapies, patients with serious cardiovascular, liver or kidney disease are not candidates for now, and a Care+ tier adds twice-yearly lab testing and around-the-clock messaging with providers. Vitamin B-12 and L-carnitine have FDA-approved prescription forms for specific established uses such as diagnosed deficiency, but the compounded wellness versions sold here are not approved for the general recovery, energy or longevity claims that drive demand.
The six peptides in the federal policy are a separate list
News coverage has tied the launch to a federal easing of peptide rules, but the two do not line up one for one, and the distinction matters. The five products Hims launched first are not the peptides named in the new federal policy. The planned additions are: Hims says it will add BPC-157 and TB-500, often combined in a recovery regimen marketed as the Wolverine stack, and said it would manufacture both in the United States.
BPC-157 and TB-500 are two of the six peptides covered by an interim HHS enforcement discretion policy. The full list is BPC-157, TB-500, Epitalon, KPV, MOTS-c and Semax. Most published research on BPC-157 and TB-500 is in animals rather than large human trials.
What the HHS policy does, and does not, do
The policy is a Notice of availability that HHS published in the Federal Register on October 30, 2026. It announces that HHS will exercise enforcement discretion for the use of certain peptide bulk drug substances in 503A compounding while the 503A bulks list is developed through rulemaking. It is not FDA approval of the peptides, it is interim, and HHS states it may revise or withdraw it. Law firms tracking the notice read it as enforcement discretion only, with a public comment window and the usual caveat that state boards of pharmacy may impose their own limits or decline to recognize the policy.
The notice follows the July 2026 vote by the FDA's Pharmacy Compounding Advisory Committee, whose members narrowly backed adding several peptides to the 503A list against the recommendation of FDA staff scientists. HHS Secretary Robert F. Kennedy Jr., who restructured that committee, has said he is a supporter of peptides and has described using BPC-157 for a muscle injury.
The evidence Hims itself flags as thin
Dr. Anant Vinjamoori, the chief medical officer of Hims, said the company does not have the clinical data it is used to having with established compounds, and that if patients are not getting results the company would adjust doses or consider other options. Andrew Huberman, the neuroscientist who recently joined the Hims board, framed the compounds as real medical treatments rather than a wellness trend and pointed to trusted sourcing and physician oversight.
The published evidence is limited. A 2026 systematic review of 113 studies found no eligible clinical outcome trials showing that intravenous or intramuscular NAD+ improves anti-aging, energy or wellness outcomes in humans. A review of 37 L-carnitine trials found an average weight change of about 2.7 pounds, which does not establish that a compounded injection would perform the same way. Vitamin B-12 injections are used mainly for diagnosed deficiency. Compounded injectable glutathione has its own safety record: the FDA received reports of at least 30 patients with adverse events, and two Texas pharmacies issued recalls over elevated endotoxin levels.
What outside experts say
- Joshua Kritzer, a chemistry professor at Tufts, said that without testing, all you have is anecdotal information, and that telehealth-only oversight is not enough supervision for an unapproved prescription medication. He said large trials are needed to rule out rare but serious complications.
- Paul Knoepfler, a professor at UC Davis, said the dosing for these products has not been established and warned that excess doses could trigger harmful immune responses. He said more physician contact is better, and that providers should review risks and patient history.
The business backdrop
Demand signals are strong: Hims opened an early-access waitlist in late October and said more than 10,000 people joined within 15 days. The economics are smaller, at least for now. When Hims previewed the launch in its November 3 third-quarter report, it narrowed full-year revenue guidance to $3.13 billion to $3.15 billion, from a prior $3.1 billion to $3.3 billion range, and the chief financial officer, Yemi Okupe, said revenue from the peptide treatments would be immaterial through the year. Shares fell more than 3 percent in after-hours trading on that report. Hims acquired a California peptide manufacturing facility in February 2025, which supports its plan to make BPC-157 and TB-500 domestically.
What this means
A publicly traded telehealth company putting compounded peptides on its storefront, with a board member who is a well-known science communicator, normalizes a category that until recently lived mostly in gray-market channels and research-use-only labels. It also exposes how fragile the legal footing is. The initial five products rely on traditional pharmacy compounding rather than the new policy, while the headline peptides Hims plans to add depend on an enforcement posture that HHS can withdraw and that individual state pharmacy boards do not have to honor. Buyers are being asked to accept products the seller itself says lack the usual evidence base.
Limits and what we are watching
This article is general information, not medical or legal advice. Anyone weighing peptide therapy should discuss the risks, the lack of FDA approval, and their own medical history with a licensed clinician, and should understand that compounded products are not reviewed by the FDA for safety or effectiveness before sale. We are watching the HHS comment period and the 503A rulemaking that will determine whether this access becomes durable or is rolled back, whether state boards accept or reject the enforcement discretion policy, and whether the FDA takes any position on the specific wellness claims attached to compounded peptides.
Frequently asked questions
Are the Hims & Hers Peptides+ products FDA approved?+
No. The products are compounded, and Hims states on its own page that they are not FDA approved and have not been evaluated by the regulator for safety, effectiveness, or quality. Compounded drugs are not reviewed by the FDA before they are sold.
Does the new federal policy cover the five products Hims launched first?+
No. Sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine are not the substances named in the October 30, 2026 HHS enforcement discretion policy. That policy covers six peptides: BPC-157, TB-500, Epitalon, KPV, MOTS-c and Semax. Hims says BPC-157 and TB-500 are planned additions.
Is the HHS enforcement discretion policy the same as FDA approval?+
No. It is interim enforcement discretion while the 503A bulks list is developed through rulemaking. HHS says it may revise or withdraw the policy, and state boards of pharmacy may impose their own restrictions or decline to recognize it.
What do independent experts say about the risks?+
Researchers quoted in the coverage said the dosing for these products has not been established, that without testing the evidence is largely anecdotal, and that excess doses could trigger harmful immune responses. Some questioned whether telehealth-only oversight is sufficient for unapproved injectable prescriptions.
What is the Wolverine stack that Hims plans to add?+
It is a recovery regimen that combines the peptides BPC-157 and TB-500, marketed for muscle, tendon and injury recovery. Both are among the six peptides in the HHS policy, both are unapproved, and most of the published research on them is in animals rather than large human trials.
Should I start peptide therapy through a telehealth platform?+
That is a decision for you and a licensed clinician, not something this article can advise. The practical points to weigh are that these products are not FDA approved for the marketed uses, that the evidence the seller cites is limited, and that the legal basis for some of them is an interim policy that could change.
Sources
- 1.Hims & Hers launches new peptide treatments, while admitting there's more to learn about efficacy · CNBC
- 2.Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (FR Doc. 2026-22192, Notice of availability) · Office of the Secretary, U.S. Department of Health and Human Services, via the Federal Register
- 3.HHS Issues Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · BakerHostetler
- 4.Hims & Hers to offer unapproved peptides to customers · pharmaphorum
- 5.Hims & Hers Peptides+ product page · Hims & Hers
- 6.Hims & Hers plans November launch of peptide treatments as higher costs weigh on profit outlook · Reuters, via Investing.com